VOLITIONRX LTD (VNRX) - Dilution Analysis

10-Q filing | 6.9M shares outstanding

10-K filing | 125.8M shares outstanding

10-Q filing | 122.8M shares outstanding

8-K filing: VolitionRx Limited completed a public offering of 11,550,000 shares of common stock with warrants and an additional underwriter option exercise of 1,194,000 shares and 1,732,500 warrants at $0.52 per share and $0.01 per warrant, less a 7.0% underwriting discount.

8-K filing: VolitionRx Limited completed an underwritten public offering of 11,550,000 shares of common stock and warrants, with an option for the underwriter to purchase an additional 1,732,500 shares and warrants; certain directors and officers purchased an aggregate of 254,229 shares and accompanying warrants. ($6.01M proceeds)

10-Q filing | 102.7M shares outstanding

8-K filing: VolitionRx Limited entered into a securities purchase agreement for the issuance and sale of shares of common stock and warrants in a registered direct offering, with gross proceeds of $1.21 million. ($0.0M proceeds)

S-3 filing: This S-3 filing registers a convertible promissory note and common stock purchase warrant offering, with the company planning to use the proceeds for working capital purposes.

10-Q filing | 96.5M shares outstanding

RW filing: VolitionRx Limited requests the withdrawal of 35,867,306 shares of common stock issuable upon the exercise of previously issued warrants due to the company being subject to the "baby shelf" rules.

S-3/A filing: The filing relates to the registration of an indeterminate number of shares of common stock, warrants, and units to be issued or issuable with respect to the securities registered as a result of stock splits, stock dividends or similar transactions.

S-1 filing: This S-1 filing relates to the issuance and sale of up to an aggregate 35,867,306 shares of common stock, consisting of Underwriter Warrant Shares, Pre-Funded Warrant Shares, Series A Warrant Shares, Series B Warrant Shares, Placement Agent Warrant Shares, Form A Warrant Shares, Form B Warrant Shares, and Investor Warrant Shares, in each case as further described in the filing.

10-K filing | 86.5M shares outstanding

8-K filing: VolitionRx Limited completed a registered direct offering of 2,363,636 shares of common stock to insiders and 1,739,087 shares of common stock and warrants to warrant investors at a combined offering price of $0.55 per share and warrant, resulting in gross proceeds of approximately $2.3 million. ($2.3M proceeds)

8-K filing: VolitionRx Limited entered into a securities purchase agreement for a registered direct offering of 445,648 shares of common stock to Insiders and 2,857,389 shares of common stock to Warrant Investors, along with warrants, at a combined offering price of $0.5722 per share and warrant, with gross proceeds of approximately $1.9 million. ($1.9M proceeds)

10-Q filing | 81.9M shares outstanding

S-3 filing: The company is filing an S-3 to register the offering of common stock, warrants exercisable for shares of common stock, or units having an aggregate initial offering price not to exceed $100,000,000.

10-Q filing | 82.9M shares outstanding

8-K filing: VolitionRx Limited completed a registered direct offering of 9,170,000 shares of common stock, pre-funded warrants to purchase 3,557,273 shares, Series A warrants to purchase 12,727,273 shares, and Series B warrants to purchase 12,727,273 shares at a price of $0.55 per share and accompanying warrants, and $0.549 per pre-funded warrant and accompanying warrants, resulting in gross proceeds of $7.0 million. ($7.0M proceeds)

S-3 filing: This is an S-3 filing for a shelf registration of common stock by a selling stockholder.

10-Q filing | 82.1M shares outstanding

10-K filing | 81.9M shares outstanding

10-Q filing | 78.3M shares outstanding

10-Q filing | 78.1M shares outstanding

8-K filing: VolitionRx Limited entered into an underwriting agreement with Freedom Capital Markets to issue and sell 13,000,000 shares of common stock at $1.27 per share, with an option for the underwriters to purchase an additional 1,950,000 shares. ($16.51M proceeds)

10-Q filing | 63.1M shares outstanding

10-K filing | 57.9M shares outstanding

8-K filing: VolitionRx Limited completed a public offering of 4,945,000 shares of common stock at $1.75 per share, resulting in net proceeds of approximately $8.0 million, which will be used for research, product development, clinical studies, commercialization, working capital, and potential acquisitions. ($8.0M proceeds)

10-Q filing | 57.5M shares outstanding

10-Q filing | 57.3M shares outstanding

8-K filing: VolitionRx Limited completed an offering of 3,450,000 shares of common stock at $2.00 per share, resulting in net proceeds of approximately $6.4 million for research and development, clinical studies, product commercialization, working capital, and potential acquisitions. ($6.9M proceeds)

10-Q filing | 53.8M shares outstanding

10-K filing | 53.8M shares outstanding

10-Q filing | 53.5M shares outstanding

S-3/A filing: This S-3/A filing registers unsold securities from a prior registration statement and new securities with an aggregate maximum offering price of $46,557,172.11.

S-3 filing: VolitionRx Limited files an S-3 form to offer up to $25,000,000 of its common stock through an Equity Distribution Agreement with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. as agents.

10-Q filing | 48.6M shares outstanding

8-K filing: VolitionRx Limited entered into an underwriting agreement with Cantor Fitzgerald & Co. for a public offering of 3,809,524 shares of common stock at a price of $4.9533 per share, with an option for the underwriter to purchase an additional 571,428 shares. ($18.9M proceeds)

S-3 filing: This S-3 filing registers 9,810,310 shares of common stock for resale by selling stockholders, including shares issuable upon exercise of outstanding warrants. The company will not receive any proceeds from the sale of these shares.